ORSOBIO, INC.
TLC-1235, a controlled-release mitochondrial protonophore small molecule therapeutic for reversing insulin resistance in lipodystrophy
- Sector
- Biotech
- Headquarters
- MENLO PARK, CA
- Founded
- 2020
- Latest Form D
- $40M, Aug 2024
- Total capital
- $127M
- Federal grants
- $2.3M
- 3 awards · 2022–2024
- Rank in peer group#468 of 514
- Private capital raised
- $125M
- 2 Form D · last Aug 2024
- 26 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 7
- 11 pending · first 2023
- Rank in peer group#48 of 514
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$40M
- Federal grantHealth and Human S · Phase II · TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy$1.0M
- Private capital raisedForm D · SEC · 1st filing$84.6M
- Federal grantHealth and Human S · Phase II · TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy$1.0M
- Federal grantHealth and Human S · Phase II · TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Federal first
14months
from ORSOBIO, INC.’s first federal award to its first private round.
- First federal award · Sep 2022
- Health and Human S · $300K
- First Form D · Nov 2023
- $84.6M · 1st Form D
- Awards before first raise
- 2 awards
An association in public records, not a cause or a prediction.
Standing among 514 peers
Line = medianBiotech · Molecule
- Federal grantsBelow median
- Granted patents#48 · top 9%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
From SEC Form D filings- Cory FreedlandDirectorNamed in SEC Form D filings
- Edward FlemingDirectorNamed in SEC Form D filings
- Evan RachlinDirectorNamed in SEC Form D filings
- Gangadhara GanapatiExecutive Officer, DirectorNamed in SEC Form D filings
- Mani SubramanianExecutive Officer, DirectorNamed in SEC Form D filings
- Matthew YoungDirectorNamed in SEC Form D filings
Show all 8 people
- Muzammil MansuriDirectorNamed in SEC Form D filings
- Srinivas AkkarajuDirectorNamed in SEC Form D filings
What it has protected
USPTO · 7 granted of 18- GrantedSulfinylaminobenzamide And Sulfonylaminobenzamide DerivativesUSPTOUS 12,606,522
- PendingLxr Modulators With Bicyclic Core Moiety For Treating DyslipidemiasUSPTOApplication 19196617
- PendingNovel Aminocarboxymuconate Semialdehyde Decarboxylase InhibitorsUSPTOApplication 18913029
Show all 18 patent records
- Sulfinylaminobenzamide And Sulfonylaminobenzamide DerivativesApr 21, 2026 · US 12,606,522Granted
- Lxr Modulators With Bicyclic Core Moiety For Treating DyslipidemiasMar 26, 2026 · Application 19196617Pending
- Novel Aminocarboxymuconate Semialdehyde Decarboxylase InhibitorsMar 19, 2026 · Application 18913029Pending
- Oxopyridine Derivatives Useful As Aminocarboxymuconate Semialdehyde Decarboxylase (acmsd) InhibitorsAug 5, 2025 · US 12,378,200Granted
- Aminocarboxymuconate Semialdehyde Decarboxylase (ACMSD) InhibitorsMay 8, 2025 · Application 19014642Pending
- Novel Lxr Modulators With Bicyclic Core MoietyMay 6, 2025 · US 12,291,523Granted
- Sulfinylaminobenzamide And Sulfonylaminobenzamide DerivativesJul 30, 2024 · US 12,049,439Granted
- Novel Lxr Modulators With Bicyclic Core MoietyApr 30, 2024 · US 11,970,484Granted
- Oxopyridine Derivatives Useful As Aminocarboxymuconate Semialdehyde Decarboxylase (acmsd) InhibitorsOct 10, 2023 · US 11,780,812Granted
- Novel Lxr Modulators With Bicyclic Core MoietyApr 4, 2023 · US 11,618,747Granted
- Novel Aminocarboxymuconate Semialdehyde Decarboxylase InhibitorsApplication 63623470Pending
- Novel Aminocarboxymuconate Semialdehyde Decarboxylase InhibitorsApplication PCTUS2024050935Pending
- Novel Aminocarboxymuconate Semialdehyde Decarboxylase InhibitorsApplication 63696524Pending
- Compounds For Modulating Energy ExpenditureApplication 63659817Pending
- Compounds For Modulating Energy ExpenditureApplication PCTUS2025033423Pending
- Lxr Modulators With Bicyclic Core Moiety For Treating DyslipidemiasApplication PCTUS2023078547Pending
- Aminocarboxymuconate Semialdehyde Decarboxylase InhibitorsApplication 63544005Pending
- Lxr Modulators With Bicyclic Core Moiety For Treating DyslipidemiasApplication 63382217Pending
Related companies, and why
- Faeth Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Aethon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- Consano Bio, Inc.Similar federal contract value in Biotech · null in contracts
- CellCentricSimilar federal contract value in Biotech · null in contracts
- Invea Therapeutics, IncSimilar federal contract value in Biotech · null in contracts
- SPOT CELLS, LLCSimilar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .